...company Adeona will acquire Hartlab, a CLIA-certified clinical lab, for $280,000 in cash. Adeona (formerly Pipex Pharmaceuticals Inc....

...Othera OT-551 Ophthalmic solution of a small molecule catalytic antioxidant derived from Tempol-H Ph II Pipex...

...AMD and diabetic macular edema (DME). MacuSight retains rights elsewhere. May 08 Pipex (AMEX:PP) Undisclosed Pipex...
...that includes E10030, a preclinical compound to treat wet AMD Jul 07 Pipex (AMEX:PP) Undisclosed Pipex...

...license from the university to develop and commercialize oral dnaJP1 (formerly AT-001) for autoimmune diseases. Pipex...
...university will receive an undisclosed upfront payment and is eligible for undisclosed milestones, plus royalties. Pipex’s...
...III testing to treat women with relapsing-remitting multiple sclerosis (MS) (see BioCentury, Nov. 7, 2005). Pipex Pharmaceuticals Inc....

...was up DKK26.5 (12%) to DKK247.5 on the week (see “NeuroSearch TIPOs the Scales,” A14). Pipex...
...acuity vs. placebo in a Phase II trial to treat dry age-related macular degeneration (AMD). Pipex...

...seconds for Zinthionein vs. increases of 0.19 and 0.54 for placebo. Zinthionein was well tolerated. Pipex Pharmaceuticals Inc....

...double-blind study of the covalently linked form of zinc-monocysteine complex enrolled 80 patients. On Wednesday, Pipex...

...holds the patents to use flupirtine for the respective indications. Financial terms were not disclosed. Pipex...
...receptor antagonist and potassium (K) channel modulator marketed since 1981 in Europe to treat pain. Pipex Pharmaceuticals Inc....